Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix

Nano Lett. 2012 Jun 13;12(6):3213-7. doi: 10.1021/nl301206p. Epub 2012 May 10.


A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Extracellular Matrix / drug effects*
  • Mammary Neoplasms, Experimental / drug therapy*
  • Mammary Neoplasms, Experimental / pathology*
  • Mice
  • Nanocapsules / administration & dosage*
  • Protein-Lysine 6-Oxidase / administration & dosage*


  • Nanocapsules
  • Protein-Lysine 6-Oxidase